During the 2nd week of January 2019, Crossject will be in San Francisco around the J.P. Morgan Healthcare Conference, to meet with American pharmaceutical companies.Read more
Patrick Alexandre: « Lorsque l’on regarde ce qui a été accompli, nous avons de réelles raisons d’être fiers. »
Patrick Alexandre, PDG de Crossject, a répondu aux questions de Didier TESTOT pour LA BOURSE ET LA VIE TV.
Crossject COO Olivier Giré will be attending the 2018 BIO One-on-One Partnering™ in Boston from June 3th to 6th.
The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.
Crossject is proud to announce that ZENEO® received the 2017 JANUS Prospective award from the French Institute of Design.
Starting in autumn, Crossject will be attending renowned international conferences in Europe and the United States.